Table E.1.
Methods and criteria used for antimicrobial susceptibility testing in referenced publications (Sections 3.3 and 3.4)
| Reference | Year published | Testing performed and breakpoints determined using |
|---|---|---|
| Aust et al. | 2013 | CLSI, 2008 (M31–A3) |
| Beneragama et al. | 2013 | Plate count method, 50 mg/L cefazolin |
| Bengtsson et al. | 2009 | CLSI (M31‐A2, formerly NCCLS, 2002) |
| Berge et al. | 2006 | CLSI (M31‐A2, formerly NCCLS, 2002) |
| Botrel et al. | 2010 | French Society Microbiology (CA‐SFM, 2007a,b) |
| BVL | 2015 | CLSI, 2013a (M100‐S23) |
| Dolejska et al. | 2008 | Literák et al., 2007; CLSI (M31‐A2, formerly NCCLS, 2002) |
| Duse et al. | 2015 | CLSI, 2013b (VET01‐A4) |
| Duse et al. | 2016 | MICs by CLSI method, EUCAST ECOFFs used |
| Kalmus et al. | 2011 | CLSI (M31‐A2, formerly NCCLS, 2002; M31‐A3, CLSI, 2008) |
| Oliver et al. | 2012 | Not stated in paper, data from many different sources |
| Pereira et al. | 2014 | CLSI, 2008 (M31‐A3) |
| Persson et al. | 2011 | CLSI, 2007 (M100‐S17) |
| Randall et al. | 2012 | MICs by BSAC method, EUCAST ECOFFs used |
| Randall et al. | 2014 | MICs by BSAC method, EUCAST ECOFFs used |
| Roesch et al. | 2006 | CLSI (M31‐A2, formerly NCCLS, 2002; M7‐A6, formerly NCCLS, 2003) |
| Thomas et al. | 2015 | CLSI (Vet01‐A4, CLSI, 2013b; Vet01‐S2, CLSI 2013c; M100‐S series) |
BSAC: British Society of Antimicrobial Chemotherapy; CLSI: Clinical and Laboratory Standards Institute; ECOFF: Epidemiological Cut‐Off value (EUCAST) to denote isolates as sensitive or resistant; EUCAST: European Committee on Antimicrobial Susceptibility Testing; NCCLS: National Committee for Clinical Laboratory Standards.